Teva Pharmaceuticals Recalls 1.46 Million Cephalexin Bottles Over CGMP Deviations
Teva Pharmaceuticals USA, Inc. initiated a Class II voluntary recall (D-0013-2021) for 1,467,535 bottles of Cephalexin for Oral Suspension due to Current Good Manufacturing Practice (CGMP) deviations. This event, now terminated, highlights critical quality control risks where active ingredient levels were potentially outside specification limits. Procurement and regulatory teams must scrutinize supplier quality systems, even for generic products, to mitigate supply chain disruptions and ensure patient safety.
FDA Mandates Recall of Teva's Cephalexin Oral Suspension Over CGMP Deficiencies
On August 24, 2020, Teva Pharmaceuticals USA, Inc. initiated a Class II voluntary recall, identified as D-0013-2021, impacting 1,467,535 bottles of Cephalexin for Oral Suspension, USP 250 mg per 5 mL. This significant recall, classified as Class II due to potential health risks where the probability of serious adverse health consequences is remote but temporary or medically reversible, was prompted by critical Current Good Manufacturing Practice (CGMP) deviations. Specifically, the investigation revealed a possibility that some bottles within the affected lots contained the active ingredient, Cephalexin, either above or below the established specification limits. For procurement directors, this event underscores the imperative of stringent supplier qualification and ongoing monitoring. A deviation in active ingredient concentration directly impacts product efficacy and patient safety, leading to potential treatment failures or adverse effects. The nationwide distribution across the U.S. and Puerto Rico meant a broad market exposure, necessitating a rapid and comprehensive recall strategy. Affected lots included various expiration dates ranging from August 2020 to November 2021, such as lot numbers 30309862A, 30309928A, 30310029A, 30310035A, 30310134A, 30310182A, 30310211A, 30310282A, 30310290A, 30310394A, 30310457A, 30310506A, 30310555A, 30310605A for 100 mL bottles, and 30309864A, 30309930A, 30309991A, 30310036A, 30310082A, 30310136A, 30310184A, 30310212A, 30310303A, 30310327A, 30310396A, 30310445A, 30310556A for 200 mL bottles. This breadth of affected inventory highlights systemic quality control vulnerabilities.
Operational Footprint: Teva Pharmaceuticals USA's Role in Cephalexin Supply
The recalling firm, Teva Pharmaceuticals USA, is headquartered at 400 Interpace Pkwy, Parsippany, NJ 07054-1120, in the United States. The product description for the recalled Cephalexin for Oral Suspension specifically identifies Teva Pharmaceuticals USA, Inc. of North Wales, PA 19454, as the manufacturer. This distinction is crucial for regulatory affairs heads and supply chain VPs, as it indicates the operational entities involved. While the source text provides these corporate addresses, it does not detail specific manufacturing facility identifiers (such as FEI numbers), production capacities, or the precise role of these locations within Teva's global API or finished product supply chain for Cephalexin. For business development executives, this lack of granular detail on manufacturing sites complicates the assessment of a supplier's operational robustness and potential single points of failure. Understanding the specific facility responsible for production is paramount for conducting comprehensive risk assessments and ensuring compliance with international regulatory standards, especially when considering the widespread distribution of this critical antibiotic.
Resolution and Compliance: Teva's Cephalexin Recall Terminated
The Class II recall for Teva's Cephalexin for Oral Suspension, initiated on August 24, 2020, was officially terminated by the FDA on December 16, 2021. This termination signifies that the FDA has deemed the firm's corrective actions sufficient to address the identified Current Good Manufacturing Practice (CGMP) deviations and the associated product quality issues. For regulatory affairs heads, the termination of a recall is a critical milestone, indicating the immediate regulatory enforcement action has concluded. However, it also serves as a reminder that robust internal quality systems must be continuously maintained to prevent recurrence. Procurement directors should leverage such events to re-evaluate their supplier audit protocols, focusing on verifying the effectiveness of corrective and preventive actions (CAPAs) implemented post-recall. While the immediate threat to supply chain continuity from this specific event has passed, the underlying cause—active ingredient levels outside specification—highlights a fundamental quality control vulnerability. Business development executives should note that consistent compliance is a key differentiator in a competitive market, influencing long-term partnerships and market trust. The timeline from initiation to termination, spanning over 15 months, underscores the extensive effort required to resolve significant quality issues and restore regulatory confidence.